Page last updated: 2024-10-19
inositol and Acrania
inositol has been researched along with Acrania in 35 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although peri-conceptional folic acid (FA) supplementation can prevent a proportion of neural tube defects (NTD), there is increasing evidence that many NTD are FA non-responsive." | 9.22 | Inositol for the prevention of neural tube defects: a pilot randomised controlled trial. ( Burren, K; Chitty, LS; Copp, AJ; Gay, V; Greene, ND; Leung, KY; Mills, K, 2016) |
| " Maternal periconceptional supplementation with folic acid significantly reduces the risk of an NTD-affected pregnancy, but does not prevent all NTDs, and "folic acid non-responsive" NTDs continue to occur." | 8.95 | Inositol, neural tube closure and the prevention of neural tube defects. ( Copp, AJ; Greene, ND; Leung, KY, 2017) |
| "Although inositol dietary deficiency in the general population has not been demonstrated at the serum level, several findings are emerging regarding the impact of inositol supplementation in periconceptional period and in early phases of pregnancy." | 8.93 | Preventive and Therapeutic Role of Dietary Inositol Supplementation in Periconceptional Period and During Pregnancy: A Summary of Evidences and Future Applications. ( Abdulrahim, B; Borgato, S; Gizzo, S; Noventa, M; Quaranta, M; Vitagliano, A, 2016) |
| "Although up to 70% of neural tube defects (NTDs) can be prevented by adequate folate consumption, some NTDs are unrelated to folate, myo-inositol was found to reduce the incidence of spinal NTDs that are unrelated to folate in curly tail mice." | 8.79 | Inositol prevents expression of a genetic model of neural tube defects in mice. ( , 1997) |
| "Supplementation with myo-inositol during the periconceptional period of pregnancy may ameliorate the recurrence risk of having a fetus affected by a neural tube defect (NTD; e." | 8.02 | Maternal Inositol Status and Neural Tube Defects: A Role for the Human Yolk Sac in Embryonic Inositol Delivery? ( Copp, AJ; D'Souza, SW; Glazier, JD; Greene, NDE, 2021) |
| "Our study aims to demonstrate that the use in the preconceptional period until the 24th week of pregnancy of inositol and folic acid, first of all, preserves the product of conception from neural tube defects (NTDs) and then, thanks to inositol supplementation, it possibly counteracts and prevents the onset of maternal gestational diabetes (GDM)." | 7.85 | Prevention of neural tube defects and maternal gestational diabetes through the inositol supplementation: preliminary results. ( Allegretti, A; Benedetto, M; Capalbo, A; D'Apice, MR; Dell'Edera, D; Epifania, AA; Lupo, MG; Sarlo, F; Simone, F, 2017) |
| "Neural tube defects (NTDs) are classified as folate sensitive (about 70%) and folate resistant (about 30%); although folic acid is able to prevent the former, several data have shown that inositol may prevent the latter." | 7.78 | Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects. ( Carlomagno, G; Cavalli, P; De Grazia, S; Unfer, V, 2012) |
| "Neural tube defects (NTDs), most commonly spina bifida and anencephaly, can be prevented with periconceptional intake of folic acid in about 70% of cases." | 7.77 | Effects of inositol supplementation in a cohort of mothers at risk of producing an NTD pregnancy. ( Cavalli, P; Grosso, E; Poggiani, C; Tonni, G, 2011) |
| "Among mouse genetic mutants that develop neural tube defects (NTDs), some respond to folic acid administration during early pregnancy, whereas NTDs in other mutants are not prevented." | 7.71 | D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects. ( Allan, G; Cogram, P; Copp, AJ; Greene, ND; Tesh, J; Tesh, S; Wade, A, 2002) |
| " The present experiment was designed to determine: 1) if hyperglycemia-induced membrane injury is associated with intracellular and/or extracellular lipid disturbances; 2) if supplemental myo-inositol therapy prevents hyperglycemia-induced embryopathy; 3) if a correlation exists between dietary myo-inositol, serum and tissue levels of myo-inositol, and conceptus development; and 4) the cellular content of arachidonic acid following myo-inositol supplementation." | 7.70 | Dietary myo-inositol therapy in hyperglycemia-induced embryopathy. ( Borenstein, M; Khandelwal, M; Reece, EA; Wu, YK, 1998) |
| " It has been reported that a substantial proportion of NTD in humans can be prevented by folic acid (FA) supplementation prior to conception and during the first months of pregnancy, and myo-inositol (MI) was shown to reduce the incidence of NTD in curly tail mice which are not prevented by FA." | 7.70 | Folic acid supplementation of pregnant mice suppresses heat-induced neural tube defects in the offspring. ( Shin, JH; Shiota, K, 1999) |
| "Clinical trials demonstrate that up to 70% of neural tube defects (NTDs) can be prevented by folic acid supplementation in early pregnancy, whereas the remaining NTDs are resistant to folate." | 7.69 | Inositol prevents folate-resistant neural tube defects in the mouse. ( Copp, AJ; Greene, ND, 1997) |
| " The current investigation was undertaken to assess the use of dietary myo-inositol supplementation as a pharmacologic prophylaxis to obviate the teratogenic effects of hyperglycemia in an in vivo study." | 7.69 | Dietary intake of myo-inositol and neural tube defects in offspring of diabetic rats. ( Borenstein, M; Khandelwal, M; Reece, EA; Wu, YK, 1997) |
| "Although peri-conceptional folic acid (FA) supplementation can prevent a proportion of neural tube defects (NTD), there is increasing evidence that many NTD are FA non-responsive." | 5.22 | Inositol for the prevention of neural tube defects: a pilot randomised controlled trial. ( Burren, K; Chitty, LS; Copp, AJ; Gay, V; Greene, ND; Leung, KY; Mills, K, 2016) |
| " Maternal periconceptional supplementation with folic acid significantly reduces the risk of an NTD-affected pregnancy, but does not prevent all NTDs, and "folic acid non-responsive" NTDs continue to occur." | 4.95 | Inositol, neural tube closure and the prevention of neural tube defects. ( Copp, AJ; Greene, ND; Leung, KY, 2017) |
| "Although inositol dietary deficiency in the general population has not been demonstrated at the serum level, several findings are emerging regarding the impact of inositol supplementation in periconceptional period and in early phases of pregnancy." | 4.93 | Preventive and Therapeutic Role of Dietary Inositol Supplementation in Periconceptional Period and During Pregnancy: A Summary of Evidences and Future Applications. ( Abdulrahim, B; Borgato, S; Gizzo, S; Noventa, M; Quaranta, M; Vitagliano, A, 2016) |
| "Neural tube defects can be prevented by folic acid, although the mechanism of this action is unclear." | 4.80 | Prevention of neural tube defects: vitamins, enzymes and genes. ( Copp, AJ, 1998) |
| "Although up to 70% of neural tube defects (NTDs) can be prevented by adequate folate consumption, some NTDs are unrelated to folate, myo-inositol was found to reduce the incidence of spinal NTDs that are unrelated to folate in curly tail mice." | 4.79 | Inositol prevents expression of a genetic model of neural tube defects in mice. ( , 1997) |
| "Inositol is closely related to the occurrence of neural tube defects (NTDs)." | 4.31 | Genetic Effects of ITPK1 Polymorphisms on the Risk of Neural Tube Defects: a Population-Based Study. ( Guan, Z; Li, S; Liang, Y; Wang, J; Wang, X; Yang, A; Zhu, Z, 2023) |
| "Supplementation with myo-inositol during the periconceptional period of pregnancy may ameliorate the recurrence risk of having a fetus affected by a neural tube defect (NTD; e." | 4.02 | Maternal Inositol Status and Neural Tube Defects: A Role for the Human Yolk Sac in Embryonic Inositol Delivery? ( Copp, AJ; D'Souza, SW; Glazier, JD; Greene, NDE, 2021) |
| "Our study aims to demonstrate that the use in the preconceptional period until the 24th week of pregnancy of inositol and folic acid, first of all, preserves the product of conception from neural tube defects (NTDs) and then, thanks to inositol supplementation, it possibly counteracts and prevents the onset of maternal gestational diabetes (GDM)." | 3.85 | Prevention of neural tube defects and maternal gestational diabetes through the inositol supplementation: preliminary results. ( Allegretti, A; Benedetto, M; Capalbo, A; D'Apice, MR; Dell'Edera, D; Epifania, AA; Lupo, MG; Sarlo, F; Simone, F, 2017) |
| "Myo-inositol (MI) deficiency is associated with an increased risk for neural tube defects (NTDs), mental disorders and metabolic diseases." | 3.83 | Quantification of plasma myo-inositol using gas chromatography-mass spectrometry. ( Guo, J; Niu, B; Shi, Y; Wang, J; Xu, C; Zhang, F; Zhang, T; Zhong, R, 2016) |
| "Neural tube defects (NTDs) are classified as folate sensitive (about 70%) and folate resistant (about 30%); although folic acid is able to prevent the former, several data have shown that inositol may prevent the latter." | 3.78 | Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects. ( Carlomagno, G; Cavalli, P; De Grazia, S; Unfer, V, 2012) |
| "Neural tube defects (NTDs), most commonly spina bifida and anencephaly, can be prevented with periconceptional intake of folic acid in about 70% of cases." | 3.77 | Effects of inositol supplementation in a cohort of mothers at risk of producing an NTD pregnancy. ( Cavalli, P; Grosso, E; Poggiani, C; Tonni, G, 2011) |
| "Among mouse genetic mutants that develop neural tube defects (NTDs), some respond to folic acid administration during early pregnancy, whereas NTDs in other mutants are not prevented." | 3.71 | D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects. ( Allan, G; Cogram, P; Copp, AJ; Greene, ND; Tesh, J; Tesh, S; Wade, A, 2002) |
| " The present experiment was designed to determine: 1) if hyperglycemia-induced membrane injury is associated with intracellular and/or extracellular lipid disturbances; 2) if supplemental myo-inositol therapy prevents hyperglycemia-induced embryopathy; 3) if a correlation exists between dietary myo-inositol, serum and tissue levels of myo-inositol, and conceptus development; and 4) the cellular content of arachidonic acid following myo-inositol supplementation." | 3.70 | Dietary myo-inositol therapy in hyperglycemia-induced embryopathy. ( Borenstein, M; Khandelwal, M; Reece, EA; Wu, YK, 1998) |
| " It has been reported that a substantial proportion of NTD in humans can be prevented by folic acid (FA) supplementation prior to conception and during the first months of pregnancy, and myo-inositol (MI) was shown to reduce the incidence of NTD in curly tail mice which are not prevented by FA." | 3.70 | Folic acid supplementation of pregnant mice suppresses heat-induced neural tube defects in the offspring. ( Shin, JH; Shiota, K, 1999) |
| "Clinical trials demonstrate that up to 70% of neural tube defects (NTDs) can be prevented by folic acid supplementation in early pregnancy, whereas the remaining NTDs are resistant to folate." | 3.69 | Inositol prevents folate-resistant neural tube defects in the mouse. ( Copp, AJ; Greene, ND, 1997) |
| " The current investigation was undertaken to assess the use of dietary myo-inositol supplementation as a pharmacologic prophylaxis to obviate the teratogenic effects of hyperglycemia in an in vivo study." | 3.69 | Dietary intake of myo-inositol and neural tube defects in offspring of diabetic rats. ( Borenstein, M; Khandelwal, M; Reece, EA; Wu, YK, 1997) |
| "Mutants that have only exencephaly are fourfold more frequent than those that have spina bifida aperta with or without exencephaly." | 2.46 | An update to the list of mouse mutants with neural tube closure defects and advances toward a complete genetic perspective of neural tube closure. ( Harris, MJ; Juriloff, DM, 2010) |
| "Valproic acid (VPA) is an anticonvulsant drug that is widely used therapeutically for a variety of neurological conditions." | 1.33 | Myo-inositol enhances teratogenicity of valproic acid in the mouse. ( Finnell, RH; Giavini, E; Massa, V; Wlodarczyk, B, 2006) |
Research
Studies (35)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (28.57) | 18.2507 |
| 2000's | 9 (25.71) | 29.6817 |
| 2010's | 12 (34.29) | 24.3611 |
| 2020's | 4 (11.43) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Guan, Z | 3 |
| Liang, Y | 1 |
| Zhu, Z | 1 |
| Yang, A | 1 |
| Li, S | 2 |
| Wang, X | 3 |
| Wang, J | 4 |
| D'Souza, SW | 1 |
| Copp, AJ | 11 |
| Greene, NDE | 2 |
| Glazier, JD | 1 |
| Facchinetti, F | 1 |
| Cavalli, P | 5 |
| D'Anna, R | 1 |
| Kandaraki, E | 1 |
| Unfer, V | 2 |
| Luo, D | 1 |
| Yue, H | 1 |
| Lyu, J | 1 |
| Yang, Y | 1 |
| Gao, T | 1 |
| Liu, Y | 1 |
| Qin, J | 1 |
| Wang, F | 2 |
| Zhang, F | 2 |
| Niu, B | 3 |
| Zhang, T | 3 |
| Zhong, R | 2 |
| Guo, J | 3 |
| Dell'Edera, D | 1 |
| Sarlo, F | 1 |
| Allegretti, A | 1 |
| Epifania, AA | 1 |
| Simone, F | 1 |
| Lupo, MG | 1 |
| Benedetto, M | 1 |
| D'Apice, MR | 1 |
| Capalbo, A | 1 |
| Li, G | 1 |
| Xie, Q | 1 |
| Han, X | 1 |
| Noventa, M | 1 |
| Vitagliano, A | 1 |
| Quaranta, M | 1 |
| Borgato, S | 1 |
| Abdulrahim, B | 1 |
| Gizzo, S | 1 |
| Greene, ND | 6 |
| Leung, KY | 2 |
| Gay, V | 1 |
| Burren, K | 1 |
| Mills, K | 1 |
| Chitty, LS | 1 |
| Shi, Y | 1 |
| Xu, C | 1 |
| Burren, KA | 1 |
| Scott, JM | 1 |
| Majerus, PW | 1 |
| Wilson, DB | 1 |
| Zhang, C | 1 |
| Nicholas, PJ | 1 |
| Wilson, MP | 1 |
| Harris, MJ | 1 |
| Juriloff, DM | 1 |
| Tonni, G | 1 |
| Grosso, E | 1 |
| Poggiani, C | 1 |
| De Grazia, S | 1 |
| Carlomagno, G | 1 |
| Benvenga, S | 1 |
| Cogram, P | 2 |
| Tesh, S | 1 |
| Tesh, J | 1 |
| Wade, A | 1 |
| Allan, G | 1 |
| Ting, SB | 1 |
| Wilanowski, T | 1 |
| Auden, A | 1 |
| Hall, M | 1 |
| Voss, AK | 1 |
| Thomas, T | 1 |
| Parekh, V | 1 |
| Cunningham, JM | 1 |
| Jane, SM | 1 |
| Hynes, A | 1 |
| Dunlevy, LP | 1 |
| Franke, B | 1 |
| Klootwijk, R | 1 |
| Lemmers, B | 1 |
| de Kovel, CG | 1 |
| Steegers-Theunissen, RP | 1 |
| Mariman, EC | 1 |
| Shaw, GM | 1 |
| Carmichael, SL | 1 |
| Yang, W | 1 |
| Schaffer, DM | 1 |
| Massa, V | 1 |
| Wlodarczyk, B | 1 |
| Giavini, E | 1 |
| Finnell, RH | 1 |
| Tedoldi, S | 1 |
| Riboli, B | 1 |
| Shaw, G | 1 |
| Hall, JG | 1 |
| Reece, EA | 2 |
| Khandelwal, M | 2 |
| Wu, YK | 2 |
| Borenstein, M | 2 |
| Corcoran, J | 1 |
| Shin, JH | 1 |
| Shiota, K | 1 |
| Cockroft, DL | 1 |
| Brook, FA | 1 |
| Baker, L | 1 |
| Piddington, R | 1 |
| Goldman, A | 1 |
| Egler, J | 1 |
| Moehring, J | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Myoinositol on Serum Asprosin Levels in Pregnant Women[NCT05943158] | 40 participants (Actual) | Interventional | 2021-06-01 | Completed | |||
| "Influence of Espresso on Adsorption of Orally Administrated Myo-inositol in Humans"[NCT01244399] | 12 participants (Actual) | Observational | 2010-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
7 reviews available for inositol and Acrania
| Article | Year |
|---|---|
An update on the use of inositols in preventing gestational diabetes mellitus (GDM) and neural tube defects (NTDs).
Topics: Animals; Diabetes, Gestational; Female; Humans; Infant, Newborn; Inositol; Insulin; Neural Tube Defe | 2020 |
Preventive and Therapeutic Role of Dietary Inositol Supplementation in Periconceptional Period and During Pregnancy: A Summary of Evidences and Future Applications.
Topics: Animals; Dietary Supplements; Female; Folic Acid; Humans; Inositol; Neural Tube Defects; Preconcepti | 2016 |
Inositol, neural tube closure and the prevention of neural tube defects.
Topics: Animals; Clinical Trials as Topic; Dietary Supplements; Disease Models, Animal; Female; Folic Acid; | 2017 |
An update to the list of mouse mutants with neural tube closure defects and advances toward a complete genetic perspective of neural tube closure.
Topics: Animals; Ciliary Motility Disorders; Disease Models, Animal; Epigenomics; Female; Folic Acid; Humans | 2010 |
Inositol prevents expression of a genetic model of neural tube defects in mice.
Topics: Animals; Gene Expression; Inositol; Mice; Mice, Neurologic Mutants; Neural Tube Defects | 1997 |
What are the molecular mechanisms of neural tube defects?
Topics: Animals; Disease Models, Animal; Drug Resistance; Female; Folic Acid; Humans; Inositol; Mice; Mice, | 1998 |
Prevention of neural tube defects: vitamins, enzymes and genes.
Topics: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Animals; Cystathionine beta-Synthase; Fem | 1998 |
Trials
1 trial available for inositol and Acrania
| Article | Year |
|---|---|
Inositol for the prevention of neural tube defects: a pilot randomised controlled trial.
Topics: Adult; Cohort Studies; Dietary Supplements; Double-Blind Method; Feasibility Studies; Female; Folic | 2016 |
Other Studies
27 other studies available for inositol and Acrania
| Article | Year |
|---|---|
Genetic Effects of ITPK1 Polymorphisms on the Risk of Neural Tube Defects: a Population-Based Study.
Topics: Case-Control Studies; Female; Genotype; Humans; Inositol; Neural Tube Defects; Polymorphism, Single | 2023 |
Maternal Inositol Status and Neural Tube Defects: A Role for the Human Yolk Sac in Embryonic Inositol Delivery?
Topics: Female; Folic Acid; Humans; Inositol; Neural Tube Defects; Pregnancy; Spinal Dysraphism; Yolk Sac | 2021 |
Neural tube defects: role of lithium carbonate exposure in embryonic neural development in a murine model.
Topics: 5'-Nucleotidase; Animals; Central Nervous System; Disease Models, Animal; Female; Glycogen Synthase | 2021 |
Prevention of neural tube defects and maternal gestational diabetes through the inositol supplementation: preliminary results.
Topics: Adult; Diabetes, Gestational; Dietary Supplements; Female; Glucose Tolerance Test; Glycated Hemoglob | 2017 |
The maternal ITPK1 gene polymorphism is associated with neural tube defects in a high-risk Chinese population.
Topics: Adult; Asian People; Case-Control Studies; China; Female; Genotype; Humans; Inositol; Inositol Phosp | 2014 |
Quantification of plasma myo-inositol using gas chromatography-mass spectrometry.
Topics: Anencephaly; Female; Gas Chromatography-Mass Spectrometry; Humans; Inositol; Male; Mass Screening; N | 2016 |
The genetic background of the curly tail strain confers susceptibility to folate-deficiency-induced exencephaly.
Topics: Animals; Diet; DNA-Binding Proteins; Female; Folic Acid; Folic Acid Deficiency; Genetic Predispositi | 2010 |
Expression of inositol 1,3,4-trisphosphate 5/6-kinase (ITPK1) and its role in neural tube defects.
Topics: Animals; Embryo, Mammalian; Humans; Inositol; Inositol Phosphates; Mice; Mice, Knockout; Molecular S | 2010 |
Effects of inositol supplementation in a cohort of mothers at risk of producing an NTD pregnancy.
Topics: Adult; Cohort Studies; Dietary Supplements; Female; Folic Acid; Heterozygote; Humans; Infant, Newbor | 2011 |
Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects.
Topics: Adult; Biological Availability; Capsules; Coffee; Female; Gelatin; Gels; Humans; Inositol; Intestina | 2012 |
(Soft) capsules of wisdom: preventing myo-inositol malabsorption caused by coffee.
Topics: Biological Availability; Capsules; Coffee; Female; Gelatin; Gels; Humans; Hypothyroidism; Inositol; | 2012 |
D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects.
Topics: Administration, Oral; Animals; Drug Resistance; Embryonic and Fetal Development; Female; Folic Acid; | 2002 |
Inositol- and folate-resistant neural tube defects in mice lacking the epithelial-specific factor Grhl-3.
Topics: Animals; DNA-Binding Proteins; Drug Resistance; Epithelium; Female; Folic Acid; Humans; Inositol; Mi | 2003 |
Specific isoforms of protein kinase C are essential for prevention of folate-resistant neural tube defects by inositol.
Topics: Animals; Blotting, Western; Disease Models, Animal; Embryo, Mammalian; Gene Expression Regulation, E | 2004 |
Phenotype of the neural tube defect mouse model bent tail is not sensitive to maternal folinic acid, myo-inositol, or zinc supplementation.
Topics: Animals; Diet; Disease Models, Animal; DNA; Embryo Loss; Female; Genotype; Inositol; Leucovorin; Lit | 2003 |
Periconceptional dietary intake of myo-inositol and neural tube defects in offspring.
Topics: Female; Humans; Inositol; Maternal Exposure; Neural Tube Defects; Pregnancy; Prenatal Exposure Delay | 2005 |
Myo-inositol enhances teratogenicity of valproic acid in the mouse.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Anticonvulsants; Drug Synergism; Embryo | 2006 |
Inositol supplementation in pregnancies at risk of apparently folate-resistant NTDs.
Topics: 5,10-Methylenetetrahydrofolate Reductase (FADH2); Adult; Cystathionine beta-Synthase; Drug Resistanc | 2008 |
Comments on inositol supplementation in pregnancies at risk of apparently folate-resistant NTDs.
Topics: Drug Resistance; Female; Folic Acid; Humans; Infant, Newborn; Inositol; Neural Tube Defects; Pregnan | 2008 |
Give the embryo a chance.
Topics: Animals; Drug Administration Schedule; Embryo, Mammalian; Female; Fertilization; Folic Acid; Hematin | 1997 |
Inositol prevents folate-resistant neural tube defects in the mouse.
Topics: Animals; Arachidonic Acid; Embryo, Mammalian; Female; Folic Acid; Gene Expression Regulation, Develo | 1997 |
Dietary intake of myo-inositol and neural tube defects in offspring of diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Embryonic and Fetal Development; Female; Hyperglycemia; In | 1997 |
Dietary myo-inositol therapy in hyperglycemia-induced embryopathy.
Topics: Animals; Arachidonic Acid; Blood Glucose; Diabetes Mellitus, Experimental; Embryo, Mammalian; Embryo | 1998 |
Folic acid supplementation of pregnant mice suppresses heat-induced neural tube defects in the offspring.
Topics: Analysis of Variance; Animals; Diet; Embryonic and Fetal Development; Female; Folic Acid; Hematinics | 1999 |
Inositol and folate resistant neural tube defects.
Topics: Adult; Female; Folic Acid; Humans; Inositol; Male; Neural Tube Defects; Pregnancy; Ultrasonography | 2002 |
Inositol deficiency increases the susceptibility to neural tube defects of genetically predisposed (curly tail) mouse embryos in vitro.
Topics: Animals; Culture Media; Culture Techniques; Disease Susceptibility; Inositol; Mice; Mice, Inbred CBA | 1992 |
Myo-inositol and prostaglandins reverse the glucose inhibition of neural tube fusion in cultured mouse embryos.
Topics: Animals; Dinoprostone; Embryo, Mammalian; Glucose; Indomethacin; Inositol; Mice; Mice, Inbred Strain | 1990 |